

# Calcium supplementation during pregnancy in low-intake populations

<b>Submission date</b> 19/03/2004	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 01/04/2004	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 10/11/2022	<b>Condition category</b> Pregnancy and Childbirth	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr José Villar

**Contact details**  
World Health Organization  
20 Avenue Appia  
Geneva-27  
Switzerland  
CH-1211  
-  
villarj@who.int

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
WHO/HRP ID 98295

# Study information

## Scientific Title

Calcium supplementation during pregnancy in low-intake populations

## Study objectives

The purpose of this trial was to determine whether calcium supplementation of pregnant women with low calcium intake reduces pre-eclampsia and preterm delivery.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

This trial was approved by:

1. The Scientific and Ethical Review Group at UNDP/UNFPA/WHO/World Bank Special Programme for Research, Development and Research Training in Human Reproduction
2. The WHO Secretariat Committee for Research into Human Subjects
3. The Institutional Review Boards of participating centres

## Study design

Multicentre double blind randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Not specified

## Study type(s)

Treatment

## Participant information sheet

## Health condition(s) or problem(s) studied

Pre-eclampsia

## Interventions

Women were assigned randomly to receive:

1. Calcium-containing tablets (1.5 g/d), one tablet three times daily (at meal time, greater than 3 hours after any iron supplements)
2. Identical placebo

Treatment continued from enrolment to delivery. Treatment was discontinued when magnesium sulphate therapy was initiated to treat pre-eclampsia or when nephrolithiasis was diagnosed, but not when pre-eclampsia or hypertension was diagnosed.

## Intervention Type

Supplement

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Calcium supplementation

**Primary outcome measure**

1. Primary maternal outcome: incidence of preeclampsia and/or eclampsia
2. Primary neonatal outcome: preterm delivery

**Secondary outcome measures**

1. Early preterm delivery (less than 32 weeks of gestation)
2. Term low birth weight (less than 2500 g; greater than or equal to 37 weeks of gestation)
3. Hospitalisation of greater than 2 days
4. Greater than or equal to 7 days in the neonatal intensive care unit
5. Foetal, neonatal, and perinatal death

**Overall study start date**

01/11/2001

**Completion date**

01/06/2003

## **Eligibility**

**Key inclusion criteria**

1. Nulliparous pregnant women less than 20 weeks gestation
2. Living in low calcium intake areas

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Female

**Target number of participants**

8500

**Total final enrolment**

8325

**Key exclusion criteria**

1. The presence of blood pressure greater than 140 and/or 90 mmHg at first antenatal visit
2. A history of chronic hypertension or renal disease
3. A history or signs and/or symptoms of nephrolithiasis, parathyroid disorders, and diseases that require digoxin, phenytoin, or tetracycline therapy

**Date of first enrolment**

01/11/2001

**Date of final enrolment**

01/06/2003

## **Locations**

**Countries of recruitment**

Argentina

Egypt

India

Peru

South Africa

Switzerland

Viet Nam

**Study participating centre**

**World Health Organization**

Geneva-27

Switzerland

CH-1211

## **Sponsor information**

**Organisation**

UNDP/UNFPA/WHO/World Bank - Special Programme of Research, Development and Research Training in Human Reproduction

**Sponsor details**

World Health Organization

20 Avenue Appia

Geneva-27  
Switzerland  
CH-1211

**Sponsor type**

Research organisation

**Website**

<http://www.who.int/reproductive-health/hrp/>

**ROR**

<https://ror.org/01f80g185>

## Funder(s)

**Funder type**

Research organisation

**Funder Name**

United Nations Development Programme (UNDP)/United Nations Population Fund (UNFPA)  
/World Health Organization (WHO)/World Bank - Special Programme of Research, Development  
and Research Training in Human Reproduction (HRP)

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan**

Not provided at time of registration

**IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		01/03/2006		Yes	No